Sebia

[𝟲𝟲𝘁𝗵 𝗔𝗦𝗛 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴 𝗮𝗻𝗱 𝗘𝘅𝗽𝗼𝘀𝗶𝘁𝗶𝗼𝗻] 🇺🇸 We are excited to attend the #ASH Annual Meeting starting December 7th in San Diego! Mark your calendar to visit the #Sebia Team at 𝗕𝗼𝗼𝘁𝗵 #𝟯𝟮𝟬𝟵 to learn about world-leading solutions for multiple #Myeloma patient testing! 🔬 🗓️ Dates: December 7th - 10th, 2024  📍 Location: San Diego, CA 🔍 Booth Number: 3209 🌐 For more information: https://lnkd.in/ei__zFPu 💬 Let’s connect at #ASH24! 🤝 #MultipleMyeloma #ASH24 #Sebiausa #Minsight #Hematology #Oncology

🔵 World Diabetes Day 🌍 reminds us that people with diabetes need to engage in daily self-management and make major lifestyle changes, and that the resulting emotional burden can cause significant distress. 📊 𝐇𝐛𝐀𝟏𝐜 𝐭𝐞𝐬𝐭𝐢𝐧𝐠 𝐢𝐬 𝐚𝐧 𝐞𝐬𝐬𝐞𝐧𝐭𝐢𝐚𝐥 𝐭𝐨𝐨𝐥 𝐢𝐧 𝐝𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭. And for patients knowing their HbA1c levels gives a tangible measure of their progress. Patients feel better able to manage their disease and make positive lifestyle changes, resulting in improved well-being and better health. Let's continue supporting and empowering everyone on this journey!✨ #WorldDiabetesDay #DiabetesManagement #HbA1c #Sebia #EmpowerPatients

🟣 World Amyloidosis Day 🌍 October 26th 𝐀𝐋 𝐀𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬 𝐢𝐬 𝐚 𝐫𝐚𝐫𝐞 𝐛𝐮𝐭 𝐬𝐞𝐫𝐢𝐨𝐮𝐬 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐚𝐟𝐟𝐞𝐜𝐭𝐢𝐧𝐠 𝐦𝐚𝐧𝐲 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐨𝐫𝐥𝐝𝐰𝐢𝐝𝐞. On this day, we highlight the importance of early detection and proper treatment. 🧬 𝐅𝐫𝐞𝐞 𝐋𝐢𝐠𝐡𝐭 𝐂𝐡𝐚𝐢𝐧𝐬 (FLC) play a crucial role in the diagnosis and monitoring of this condition. Using FLC tests allows for early detection of abnormalities, enabling quick and appropriate intervention. Sebia offers global solutions to help diagnosing and monitoring AL Amyloidosis, from FLC assays to 🧪 Serum / Urine Protein Electrophoresis and Immunotyping / Immunofixation. 🎬Watch our 𝐰𝐞𝐛𝐢𝐧𝐚𝐫 𝐫𝐞𝐩𝐥𝐚𝐲 𝐨𝐧 𝐀𝐋 𝐀𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬 to learn more: https://lnkd.in/eGV6cug3 Together, let's raise awareness and support research to improve the lives of those affected by AL Amyloidosis. 💪 #WorldALAmyloidosisDay #ALAmyloidosis #Health #FLC #EarlyDiagnosis #Bethelink

📅 Mark Your Calendar for an Insightful Educational Webinar! Join us on November 13, 2024, at 1:00 PM EDT for an in-depth discussion on the use of Capillary Electrophoresis for Hemoglobinopathy and Thalassemia Evaluation with a focus on real-world, case-based approaches. Our expert panel includes: 🩺 Dr. Mark Girton & 🩺 Dr. Matthew C. Wagner Together, they will review complex patient cases and explore the latest advancements in capillary electrophoresis for hemoglobinopathies, including thalassemia diagnosis and management. Whether you’re a seasoned lab professional or looking to deepen your knowledge in this area, this webinar is a must-attend! ✅ Secure your spot today and gain valuable insights into how capillary electrophoresis can improve patient outcomes. 🔗 Register here: https://lnkd.in/dy5GMKiC #Hemoglobinopathy #Thalassemia #CapillaryElectrophoresis #LabScience #LabTesting #Webinar #Sebia

🟠 World Arthritis day 🌍 October 12th 𝐃𝐢𝐝 𝐲𝐨𝐮 𝐤𝐧𝐨𝐰 𝐭𝐡𝐚𝐭 #𝐀𝐫𝐭𝐡𝐫𝐢𝐭𝐢𝐬 𝐚𝐧𝐝 𝐦𝐮𝐬𝐜𝐮𝐥𝐨𝐬𝐤𝐞𝐥𝐞𝐭𝐚𝐥 𝐝𝐢𝐬𝐞𝐚𝐬𝐞𝐬 𝐚𝐟𝐟𝐞𝐜𝐭𝐬 𝐨𝐯𝐞𝐫 𝟏𝟐𝟎 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐩𝐞𝐨𝐩𝐥𝐞, 𝐚𝐟𝐟𝐞𝐜𝐭𝐢𝐧𝐠 𝐛𝐨𝐭𝐡 𝐜𝐡𝐢𝐥𝐝𝐫𝐞𝐧 𝐚𝐧𝐝 𝐚𝐝𝐮𝐥𝐭𝐬? Rheumatic and Musculoskeletal Diseases (RMDs) significantly reduce quality of life, limiting the ability to work, and participating in the social life👥. 🔍 𝐒𝐲𝐦𝐩𝐭𝐨𝐦𝐬 𝐨𝐟 #𝐑𝐌𝐃𝐬 The disorders cause 𝐩𝐚𝐢𝐧, 𝐬𝐭𝐢𝐟𝐟𝐧𝐞𝐬𝐬, 𝐚𝐧𝐝 𝐢𝐧𝐟𝐥𝐚𝐦𝐦𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐭𝐡𝐞 𝐣𝐨𝐢𝐧𝐭𝐬, 𝐦𝐮𝐬𝐜𝐥𝐞𝐬, 𝐨𝐫𝐠𝐚𝐧𝐬, 𝐭𝐞𝐧𝐝𝐨𝐧𝐬. 🩺 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐨𝐟𝐟𝐞𝐫𝐞𝐝 𝐛𝐲 #𝐒𝐞𝐛𝐢𝐚 We assist healthcare professionals in diagnosing by detecting specific autoantibodies like rheumatoid factor and anti-cyclic citrullinated peptide (CCP) 💉: https://lnkd.in/di7jZZyz ❇️ 𝐄𝐚𝐫𝐥𝐲 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 -> 𝐄𝐚𝐫𝐥𝐲 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 Discover how it is easy to implement the anti-MCV test in your lab, reducing the time to diagnose. 👉 Watch the webinar: https://lnkd.in/eEYDSHVM Together, let’s improve the diagnosis of Arthritis and musculoskeletal diseases 🤝 #HealthAwareness #RheumatoidArthritis #MusculoskeletalHealth #WorldArthritisDay #AutoimmuneDisease #Autoimmunity #HealthAwareness

🌟 Highlights from the International Myeloma Society Conference in Rio 🇧🇷 Last week, we had the opportunity to attend the #IMS2024! The session 𝐌𝐑𝐃 𝐈𝐒 𝐀𝐍 𝐄𝐍𝐃 𝐏𝐎𝐈𝐍𝐓: 𝐎𝐔𝐑 𝐒𝐔𝐂𝐂𝐄𝐒𝐒 𝐒𝐓𝐎𝐑𝐘 🌟 highlighted the amazing work and data provided by the Myeloma Community that lead the ODAC (Oncologic Drugs Advisory Committee) of the FDA to acknowledge the use of MRD as an intermediate endpoint to support accelerated approval in 𝐍𝐃𝐌𝐌 and 𝐑𝐑𝐌𝐌. 🔬It also raised the need for high-sensitive, dynamic and non-invasive assessment of MRD. 👥 Connecting with patients, clinicians and pharma companies at IMS, we had great discussions sharing the added value of our 𝐂𝐥𝐨𝐧𝐨𝐭𝐲𝐩𝐢𝐜 𝐏𝐞𝐩𝐭𝐢𝐝𝐞𝐬 𝐌𝐚𝐬𝐬 𝐒𝐩𝐞𝐜𝐭𝐫𝐨𝐦𝐞𝐭𝐫𝐲 𝐭𝐞𝐬𝐭 for MRD monitoring in blood🩸. 𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐨𝐮𝐫 𝐭𝐞𝐚𝐦 💬 𝐭𝐨 𝐤𝐧𝐨𝐰 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐌-𝐢𝐧𝐒𝐢𝐠𝐡𝐭! Pauline Fontaine, Pharm.D., Ph.D., M.Res., Caroline Rougé Dubroc, Pharm.D., Vincent BONIFAY, Youssef Maakaroun 🔗𝐌-𝐢𝐧𝐒𝐢𝐠𝐡𝐭: https://lnkd.in/eK7nhu48 #Myeloma #MultipleMyeloma #MRD #MassSpectrometry #InnovationInHealthcare #Peptides #MInSight

🌍 World Alcohol-Free Day Alcohol abuse and addiction has harmful consequences on individuals, society and economy. However, effective testing can significantly reduce these impacts: 🚗 Reduce drink driving 🩺 Improve clinical outcome ✈ Decrease accidents in major industries such as air and rail transport 𝑫𝒊𝒅 𝒚𝒐𝒖 𝒌𝒏𝒐𝒘? 𝐂𝐃𝐓 (Carbohydrate Deficient Transferrin) is a specific biomarker to detect chronic alcohol abuse. By incorporating CDT testing, we can help create safer environments, promote better health outcomes, and reduce risks in highly sensitive industries. 🎦 Watch the webinar About 𝐭𝐡𝐞 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐜𝐞 𝐨𝐟 𝐂𝐃𝐓 𝐦𝐚𝐫𝐤𝐞𝐫 𝐟𝐨𝐫 𝐜𝐡𝐫𝐨𝐧𝐢𝐜 𝐚𝐥𝐜𝐨𝐡𝐨𝐥 𝐚𝐛𝐮𝐬𝐞 𝐚𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭: https://lnkd.in/ehpijhU7 🔎 Learn more 𝐇𝐨𝐰 #𝐒𝐞𝐛𝐢𝐚 𝐜𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐞𝐬 𝐭𝐨 𝐫𝐞𝐝𝐮𝐜𝐞 𝐭𝐡𝐞 𝐢𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐞𝐱𝐜𝐞𝐬𝐬𝐢𝐯𝐞 𝐜𝐡𝐫𝐨𝐧𝐢𝐜 𝐚𝐥𝐜𝐨𝐡𝐨𝐥 𝐜𝐨𝐧𝐬𝐮𝐦𝐩𝐭𝐢𝐨𝐧: https://lnkd.in/dzNQTH-u #WorldAlcoholFreeDay #AlcoholAwareness #Alcoholtesting #bloodalcoholtesting #FAS

🚴♀️ 𝐌𝐲𝐞𝐥𝐨𝐦𝐚 𝐔𝐊 𝐑𝐢𝐝𝐞 𝐟𝐨𝐫 𝐚 𝐜𝐚𝐮𝐬𝐞 𝐜𝐥𝐨𝐬𝐞 𝐭𝐨 𝐨𝐮𝐫 𝐡𝐞𝐚𝐫𝐭𝐬💜! We're incredibly proud to announce that Sebia employees & partners have come together to raise an amazing €25,208 in support of the Myeloma UK Association during 🚴♀️〰️ the 450-kilometer cycling ride from London 🇬🇧 to Paris 🇫🇷. 🌟 𝐘𝐨𝐮𝐫 𝐠𝐞𝐧𝐞𝐫𝐨𝐮𝐬 𝐜𝐨𝐧𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧𝐬 are making a real impact, and together we are helping to improve the lives of patients affected by #Myeloma. Despite facing tough conditions, with heavy rain, our 7 determined Sebia riders pushed through to cross the finish line with smiles all the way 😃! We’re incredibly proud of our team👏 for showing what it means to turn passion into action and contribute to such an important cause. Let's keep this momentum going! Learn more and support the cause here: 🔗 Myeloma UK Bike Ride: https://lnkd.in/erX9Mhzr 🔗 Myeloma organisation in the UK: https://lnkd.in/eSVuRYV2 #MyelomaAwareness #Myeloma #Sebia #CyclingForACause #BloodCancerAwareness

[𝟮𝟭𝘀𝘁 𝗜𝗠𝗦 𝗔𝗻𝗻𝘂𝗮𝗹 𝗠𝗲𝗲𝘁𝗶𝗻𝗴] Don’t forget to join us today in the #Poster area to see our 2 Posters highlighting blood-based mass spectrometry for tracking Myeloma in patients. 📍 Location: Exhibit Hall, Pavilion 3 🕚 Viewing time: 10:30 AM - 4:00 PM 🕚 Presentation time: 12:30 PM - 1:30 PM 𝗣-𝟭𝟲𝟳: Urine Bence Jones proteins as a novel source for de novo light chain sequencing 𝗣-𝟭𝟴𝟬: MRD Tracking in Blood using a de novo sequencing from SPEP gel of M-Protein in Multiple Myeloma #IMS24 #multiplemyeloma #minsight #MRD #bloodbasedMRD

Sebia joins the International Myeloma Foundation for #𝗕𝗹𝗼𝗼𝗱𝗖𝗮𝗻𝗰𝗲𝗿𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀𝗠𝗼𝗻𝘁𝗵. Throughout the month of September, one simple question will be asked: “𝗗𝗼 𝗬𝗼𝘂 𝗞𝗻𝗼𝘄 𝗠𝘆𝗲𝗹𝗼𝗺𝗮?" 𝐌𝐢𝐧𝐢𝐦𝐚𝐥 𝐑𝐞𝐬𝐢𝐝𝐮𝐚𝐥 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 (#MRD) 𝐧𝐞𝐠𝐚𝐭𝐢𝐯𝐢𝐭𝐲 𝐢𝐧 𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞 #𝐌𝐲𝐞𝐥𝐨𝐦𝐚 is linked to improved clinical outcomes. 🔬However, current 𝐌𝐑𝐃 𝐞𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧 methods require painful bone marrow aspirates and offer limited timepoints for MRD assessment.There is a pressing need for ultra-sensitive techniques such as Mass Spectrometry that enable MRD monitoring through blood tests. Pioneering advanced techniques, M-inSight® provides innovative solutions for improved monitoring of Multiple Myeloma. 👉 Discover more about M-inSight®: https://lnkd.in/ewRTp-3k #KNOWMYELOMA #MyelomaAwareness #CancerAwareness #Healthcare #SupportPatients #MultipleMyeloma #cancer #Massspectrometry #Minimalresidualdisease #MinSight